Moleculin Biotech, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Moleculin Biotech, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | $0 | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | $0 | Mar 22, 2024 |
| FY2022 | Dec 31, 2021 | $0 | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $0 | Mar 24, 2022 |
| FY2020 | Dec 31, 2019 | $0 | Mar 24, 2021 |
| FY2019 | Dec 31, 2018 | $0 | Mar 19, 2020 |
| FY2018 | Dec 31, 2017 | $0 | Feb 21, 2019 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $0 | Mar 28, 2018 |
| FY2017 | Dec 31, 2016 | $0 | Mar 28, 2018 |
| FY2016 | Dec 31, 2015 | $0 | Apr 3, 2017 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($33.56M) | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | ($26.05M) | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | ($29.77M) | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | ($29.03M) | Mar 22, 2024 |
| FY2022 | Dec 31, 2021 | ($15.89M) | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | ($17.36M) | Mar 24, 2022 |
| FY2020 | Dec 31, 2019 | ($13.21M) | Mar 24, 2021 |
| FY2019 | Dec 31, 2018 | ($11.88M) | Mar 19, 2020 |
| FY2018 | Dec 31, 2017 | ($9.81M) | Feb 21, 2019 |
| FY2017 | Dec 31, 2016 | ($3.93M) | Mar 28, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($25.10M) | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | ($26.64M) | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | ($29.63M) | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | ($30.64M) | Mar 22, 2024 |
| FY2022 | Dec 31, 2021 | ($22.97M) | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | ($19.74M) | Mar 24, 2022 |
| FY2020 | Dec 31, 2019 | ($17.52M) | Mar 24, 2021 |
| FY2019 | Dec 31, 2018 | ($15.03M) | Mar 19, 2020 |
| FY2018 | Dec 31, 2017 | ($8.65M) | Feb 21, 2019 |
| FY2017 | Dec 31, 2016 | ($3.88M) | Mar 28, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.89M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $17.73M | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | $19.49M | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | $18.97M | Mar 22, 2024 |
| FY2022 | Dec 31, 2021 | $14.42M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $12.76M | Mar 24, 2022 |
| FY2020 | Dec 31, 2019 | $11.01M | Mar 24, 2021 |
| FY2019 | Dec 31, 2018 | $9.73M | Mar 19, 2020 |
| FY2018 | Dec 31, 2017 | $4.55M | Feb 21, 2019 |
| FY2017 | Dec 31, 2016 | $1.50M | Mar 28, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($22.74M) | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | ($23.86M) | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | ($23.59M) | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | ($27.64M) | Mar 22, 2024 |
| FY2022 | Dec 31, 2021 | ($18.95M) | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | ($17.77M) | Mar 24, 2022 |
| FY2020 | Dec 31, 2019 | ($17.20M) | Mar 24, 2021 |
| FY2019 | Dec 31, 2018 | ($12.20M) | Mar 19, 2020 |
| FY2018 | Dec 31, 2017 | ($7.32M) | Feb 21, 2019 |
| FY2017 | Dec 31, 2016 | ($3.77M) | Mar 28, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $13.0K | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | $124.0K | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | $67.0K | Mar 22, 2024 |
| FY2022 | Dec 31, 2021 | $19.0K | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $376.0K | Mar 24, 2022 |
| FY2020 | Dec 31, 2019 | $52.0K | Mar 24, 2021 |
| FY2019 | Dec 31, 2018 | $417.0K | Mar 19, 2020 |
| FY2018 | Dec 31, 2017 | $28.0K | Feb 21, 2019 |
| FY2017 | Dec 31, 2016 | $21.0K | Mar 28, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $22.13M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $16.93M | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | $38.22M | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | $57.42M | Mar 22, 2024 |
| FY2022 | Dec 31, 2021 | $84.09M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $29.03M | Mar 24, 2022 |
| FY2020 | Dec 31, 2019 | $25.24M | Mar 24, 2021 |
| FY2019 | Dec 31, 2018 | $19.59M | Mar 19, 2020 |
| FY2018 | Dec 31, 2017 | $19.48M | Feb 21, 2019 |
| FY2017 | Dec 31, 2016 | $16.39M | Mar 28, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.12M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $5.72M | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | $12.14M | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | $5.23M | Mar 22, 2024 |
| FY2022 | Dec 31, 2021 | $5.10M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $11.27M | Mar 24, 2022 |
| FY2020 | Dec 31, 2019 | $9.66M | Mar 24, 2021 |
| FY2019 | Dec 31, 2018 | $5.31M | Mar 19, 2020 |
| FY2018 | Dec 31, 2017 | $2.37M | Feb 21, 2019 |
| FY2017 | Dec 31, 2016 | $1.43M | Mar 28, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.01M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $11.21M | Mar 18, 2026 |
| FY2025 | Dec 31, 2023 | $30.93M | Mar 18, 2026 |
| FY2024 | Dec 31, 2022 | $52.19M | Mar 21, 2025 |
| FY2023 | Dec 31, 2021 | $78.99M | Mar 22, 2024 |
| FY2022 | Dec 31, 2020 | $17.76M | Mar 22, 2023 |
| FY2021 | Dec 31, 2019 | $15.57M | Mar 24, 2022 |
| FY2020 | Dec 31, 2018 | $14.27M | Mar 24, 2021 |
| FY2019 | Dec 31, 2017 | $17.12M | Mar 19, 2020 |
| FY2018 | Dec 31, 2016 | $14.96M | Feb 21, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($206.00M) | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | ($172.44M) | Mar 18, 2026 |
| FY2025 | Jan 1, 2024 | ($146.40M) | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | ($131.60M) | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | ($101.84M) | Mar 22, 2024 |
| FY2022 | Dec 31, 2021 | ($72.81M) | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | ($56.92M) | Mar 24, 2022 |
| FY2020 | Dec 31, 2019 | ($39.56M) | Mar 24, 2021 |
| FY2019 | Dec 31, 2018 | ($26.36M) | Mar 19, 2020 |
| FY2018 | Dec 31, 2017 | ($14.48M) | Feb 21, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.88M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $4.28M | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | $23.55M | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | $43.15M | Mar 22, 2024 |
| FY2022 | Dec 31, 2021 | $70.90M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $15.17M | Mar 24, 2022 |
| FY2020 | Dec 31, 2019 | $10.74M | Mar 24, 2021 |
| FY2019 | Dec 31, 2018 | $7.13M | Mar 19, 2020 |
| FY2018 | Dec 31, 2017 | $7.71M | Feb 21, 2019 |
| FY2018 | Dec 31, 2016 | $5.01M | Feb 21, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (28) | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | (189) | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | (15) | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | (15) | Mar 22, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 22, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3.20M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | 135,155 | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | 2.23M | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | 1.91M | Mar 22, 2024 |
| FY2021 | Dec 31, 2021 | 28.58M | Mar 24, 2022 |
| FY2021 | Dec 31, 2020 | 11.54M | Mar 24, 2022 |
| FY2020 | Dec 31, 2019 | 7.62M | Mar 24, 2021 |
| FY2019 | Dec 31, 2018 | 28.53M | Mar 19, 2020 |
| FY2018 | Dec 31, 2017 | 21.47M | Feb 21, 2019 |
| FY2017 | Dec 31, 2016 | 12.16M | Mar 28, 2018 |